IN2012DN01827A - - Google Patents

Download PDF

Info

Publication number
IN2012DN01827A
IN2012DN01827A IN1827DEN2012A IN2012DN01827A IN 2012DN01827 A IN2012DN01827 A IN 2012DN01827A IN 1827DEN2012 A IN1827DEN2012 A IN 1827DEN2012A IN 2012DN01827 A IN2012DN01827 A IN 2012DN01827A
Authority
IN
India
Prior art keywords
adenoviral vectors
adenoviral
serotype
heterologous sequences
antigens
Prior art date
Application number
Inventor
Timothy P Mayall
Jeff Alexander
Original Assignee
Paxvax Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Paxvax Inc filed Critical Paxvax Inc
Publication of IN2012DN01827A publication Critical patent/IN2012DN01827A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/235—Adenoviridae
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/07—Bacillus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C12N15/861—Adenoviral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/542—Mucosal route oral/gastrointestinal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/543—Mucosal route intranasal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10111—Atadenovirus, e.g. ovine adenovirus D
    • C12N2710/10141—Use of virus, viral particle or viral elements as a vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Epidemiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Mycology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

The present invention provides replication competent adenoviral vectors capable of expressing antigens from infectious pathogens, such as influenza virus. The adenoviral vectors can be used to vaccinate subjects against the infectious pathogens. The adenoviral vectors comprise heterologous sequences encoding the antigens. The heterologous sequences can be inserted into various locations in the adenoviral vectors, including in or near specific E3 deletions and/or integrated into the adenoviral hexon coding region. The adenoviral vectors can be derived from any adenoviral serotype, particularly an Ad4 or Ad7 serotype.
IN1827DEN2012 2009-07-31 2010-07-30 IN2012DN01827A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US23061709P 2009-07-31 2009-07-31
PCT/US2010/043951 WO2011014794A1 (en) 2009-07-31 2010-07-30 Adenoviral-based vectors

Publications (1)

Publication Number Publication Date
IN2012DN01827A true IN2012DN01827A (en) 2015-06-05

Family

ID=43529721

Family Applications (1)

Application Number Title Priority Date Filing Date
IN1827DEN2012 IN2012DN01827A (en) 2009-07-31 2010-07-30

Country Status (13)

Country Link
US (2) US8865182B2 (en)
EP (1) EP2459716B1 (en)
JP (1) JP5903045B2 (en)
KR (1) KR20120052369A (en)
CN (1) CN102549152B (en)
AU (1) AU2010278797A1 (en)
BR (1) BR112012008060A2 (en)
CA (1) CA2769752A1 (en)
ES (1) ES2603779T3 (en)
IN (1) IN2012DN01827A (en)
MX (1) MX2012001404A (en)
RU (1) RU2012107702A (en)
WO (1) WO2011014794A1 (en)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102549152B (en) 2009-07-31 2015-11-25 帕克斯瓦克斯股份有限公司 Based on the carrier of adenovirus
CN103154021A (en) * 2010-08-16 2013-06-12 威斯特解剖及生物研究所 Universal influenza a vaccines
AU2012222150A1 (en) * 2011-02-24 2013-09-26 Paxvax, Inc. Formulations useful for spray drying vaccines
US10183069B2 (en) 2011-03-21 2019-01-22 Altimmune Inc. Rapid and prolonged immunologic-therapeutic
CN102775469B (en) * 2011-05-12 2018-02-09 厦门大学 Epitope of influenza A virus nucleocapsid protein and application thereof
US20140377295A1 (en) * 2011-05-23 2014-12-25 The Wistar Institute Of Anatomy And Biology Influenza vaccines containing modified adenovirus vectors
US20130189303A1 (en) * 2011-08-02 2013-07-25 Yan Zhou Recombinant swine influenza virus and uses thereof
CN103987726B (en) 2011-10-05 2017-10-03 金维克有限公司 Monkey (gorilla) adenovirus or adenoviral vector and methods of use thereof
BR112014008167B1 (en) 2011-10-05 2022-05-24 Genvec Inc Adenovirus or adenoviral vector and composition comprising them
US9629906B2 (en) 2011-10-05 2017-04-25 Genvec, Inc. Affenadenovirus (gorilla) or adenoviral vectors and methods of use
US20140302124A1 (en) * 2011-10-19 2014-10-09 Immunotape, Inc. Cytotoxic T Lymphocyte Inducing Immunogens For Prevention Treatment and Diagnosis of INFLUENZA VIRUS INFECTION
HK1210475A1 (en) * 2012-05-29 2016-04-22 Genvec, Inc. Herpes simplex virus vaccine
WO2013181128A1 (en) 2012-05-29 2013-12-05 Genvec, Inc. Modified serotype 28 adenoviral vectors
RU2507258C1 (en) * 2012-08-21 2014-02-20 Общество с ограниченной ответственностью "НТфарма" Recombinant pseudo adenoviral particle based on human being adenovirus genome of 5-th serotype for induction of specific immunity to influenza virus a of h3n2 subtype and method of its use
KR102089121B1 (en) 2013-03-14 2020-03-13 더 솔크 인스티튜트 포 바이올로지칼 스터디즈 Oncolytic adenovirus compositions
US10736840B2 (en) 2013-09-03 2020-08-11 Georgia Tech Research Corporation Thermally stable vaccine formulations and microneedles
EP3110953A1 (en) * 2014-02-28 2017-01-04 Janssen Vaccines & Prevention B.V. Replicating recombinant adenovirus vectors, compositions, and methods of use thereof
US10617729B2 (en) 2014-12-24 2020-04-14 The Uab Research Foundation Multitargeting onocolytic adenovirus, methods of use, and methods of making
EA038402B9 (en) * 2015-06-12 2021-09-22 Глаксосмитклайн Байолоджикалс Са Adenovirus polynucleotides and polypeptides
KR20180101529A (en) * 2016-01-15 2018-09-12 이투빅스 코포레이션 Methods and compositions for influenza vaccination
CN105567736B (en) * 2016-02-03 2020-03-20 河南农业大学 Construction and application of E3-deleted region replication complete type recombinant adenovirus type 4 vector system
EP3390645B1 (en) 2016-02-23 2022-09-14 Salk Institute for Biological Studies Exogenous gene expression in therapeutic adenovirus for minimal impact on viral kinetics
AU2017222568B2 (en) 2016-02-23 2020-09-10 Salk Institute For Biological Studies High throughput assay for measuring adenovirus replication kinetics
CN107841513B (en) * 2016-09-18 2023-04-14 中国科学院上海巴斯德研究所 Broad-spectrum influenza vaccine based on M2e epitope
WO2018111767A1 (en) 2016-12-12 2018-06-21 Salk Institute For Biological Studies Tumor-targeting synthetic adenoviruses and uses thereof
KR20190129032A (en) * 2016-12-28 2019-11-19 인벡스, 인크. Influenza vaccine
CN107686843A (en) * 2017-09-11 2018-02-13 南方医科大学 A kind of expression vector and its construction method based on adenovirus AdC6
WO2019076877A1 (en) * 2017-10-16 2019-04-25 Glaxosmithkline Biologicals Sa Replication competent adenoviral vectors
BR112020008435A2 (en) * 2017-10-31 2020-11-17 Janssen Vaccines & Prevention B.V. adenovirus vectors and their uses
GB201804473D0 (en) * 2018-03-21 2018-05-02 Valo Therapeutics Oy Modified oncolytic adenoviruses
EP3775175A4 (en) 2018-04-09 2022-02-09 Salk Institute for Biological Studies COMPOSITIONS OF ONCOLYTIC ADENOVIRUS WITH INCREASED REPLICATION PROPERTIES
CN109504801A (en) * 2018-11-22 2019-03-22 李越希 A kind of RPA method, its primer special and probe and purposes detecting 21 type adenovirus hominis
CN109504800A (en) * 2018-11-22 2019-03-22 李越希 A kind of RPA method for detecting universal adenovirus hominis, its primer special and probe and purposes
CN109504802A (en) * 2018-11-22 2019-03-22 李越希 A kind of RPA method, its primer special and probe and purposes detecting 11/55 type adenovirus hominis
CN111057685B (en) * 2019-07-27 2022-03-18 中国人民解放军军事科学院军事医学研究院 Replication type 4 adenovirus vector recombinant Marburg virus disease vaccine
CN111057716B (en) * 2019-07-27 2022-04-15 中国人民解放军军事科学院军事医学研究院 Single plasmid vector system for packaging recombinant human adenovirus type 4 and application thereof
CN113908265B (en) * 2020-07-10 2024-03-15 上海市公共卫生临床中心 Human type 4 and type 7 adenovirus attenuated live vaccine and application thereof
WO2023009264A1 (en) * 2021-07-26 2023-02-02 Think Therapeutics, Inc. Compositions for optimized influenza peptide vaccines
WO2023015276A1 (en) * 2021-08-06 2023-02-09 Theravax, Inc. Adenoviral vector-based vaccine for emerging viruses

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA858044B (en) 1984-11-01 1987-05-27 American Home Prod Oral vaccines
AU6133394A (en) 1993-02-09 1994-08-29 Scripps Research Institute, The Targeting and delivery of genes and antiviral agents into cells by the adenovirus penton
US6127525A (en) 1995-02-21 2000-10-03 Cornell Research Foundation, Inc. Chimeric adenoviral coat protein and methods of using same
AU4255397A (en) * 1996-09-06 1998-03-26 Trustees Of The University Of Pennsylvania, The Chimpanzee adenovirus vectors
US7232899B2 (en) 1996-09-25 2007-06-19 The Scripps Research Institute Adenovirus vectors, packaging cell lines, compositions, and methods for preparation and use
ES2255181T3 (en) 1997-08-05 2006-06-16 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw. IMMUNOPROTECTOR ANTIGEN AGAINST THE FLU AND ITS USE IN VACCINATION.
CA2323235A1 (en) * 1998-04-24 1999-11-04 Onyx Pharmaceuticals, Inc. Adenoviral vectors for treating disease
US7829329B2 (en) 1998-04-24 2010-11-09 Onyx Pharmaceuticals, Inc. Adenoviral vectors for treating disease
WO2000012738A1 (en) 1998-08-27 2000-03-09 Aventis Pharma S.A. Targeted adenovirus vectors for delivery of heterologous genes
AU2001263689B2 (en) * 2000-05-31 2007-03-22 University Of Saskatchewan Modified bovine adenovirus having altered tropism
CA2435000C (en) 2001-01-18 2014-03-25 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw Oligomeric complexes of chimeric proteins with enhanced immunogenic potential
AU2003241268A1 (en) 2002-02-05 2003-09-09 Cornell Research Foundation, Inc. Adenoviral vector with replication-dependent transgene expression
CA2527721C (en) * 2003-06-10 2016-05-10 University Of Saskatchewan Chimeric adenovirus capsid proteins
US7144712B2 (en) 2003-07-30 2006-12-05 Vaccine Research Institute Of San Diego Human hepatitis B virus core proteins as vaccine platforms and methods of use thereof
AU2005243730B2 (en) 2004-04-12 2010-05-27 Genvec, Inc. Method of using adenoviral vectors to induce an immune response
US20060292682A1 (en) * 2004-07-22 2006-12-28 Hawkins Lynda K Addition of transgenes into adenoviral vectors
US8926987B2 (en) 2004-11-18 2015-01-06 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Replication-competent adenoviral vectors
US20070003576A1 (en) 2004-12-09 2007-01-04 Andrea Gambotto Vaccines for the rapid response to pandemic avian influenza
CA2609276A1 (en) 2005-05-23 2006-11-30 De-Chu C. Tang Rapid production of adenovirus-free recombinant adenovirus vectors
WO2007050128A2 (en) 2005-05-31 2007-05-03 Vectorlogics, Inc. Shielded adenoviral vectors and methods of use
US20070249043A1 (en) 2005-12-12 2007-10-25 Mayall Timothy P Adenoviral expression vectors
WO2007095056A2 (en) 2006-02-09 2007-08-23 Genzyme Corporation Slow intraventricular delivery
CN103122360A (en) 2006-02-28 2013-05-29 瓦克萨特公司 Chimeric adenoviral vectors
CN101437538A (en) 2006-04-28 2009-05-20 宾夕法尼亚州立大学托管会 Modified adenovirus hexon protein and uses thereof
EP2023952B1 (en) 2006-05-18 2015-07-15 Epimmune Inc. Inducing immune responses to influenza virus using polypeptide and nucleic acid compositions
EP2069376A4 (en) 2006-07-21 2013-10-16 Pharmexa Inc Inducing cellular immune responses to influenza virus using peptide and nucleic acid compositions
CA2658805A1 (en) * 2006-07-28 2008-01-31 Commonwealth Scientific And Industrial Research Organisation Methods and compositions for increasing tissue tropism of recombinant adenoviral vectors
CN101358202B (en) 2007-07-30 2011-02-09 中国农业科学院哈尔滨兽医研究所 Recombinant canine type 2 adenovirus transfer vector, its construction method and application
CN102549152B (en) * 2009-07-31 2015-11-25 帕克斯瓦克斯股份有限公司 Based on the carrier of adenovirus

Also Published As

Publication number Publication date
JP5903045B2 (en) 2016-04-13
BR112012008060A2 (en) 2016-11-22
CN102549152A (en) 2012-07-04
EP2459716A4 (en) 2013-06-19
AU2010278797A1 (en) 2012-03-15
JP2013501001A (en) 2013-01-10
CA2769752A1 (en) 2011-02-03
KR20120052369A (en) 2012-05-23
CN102549152B (en) 2015-11-25
ES2603779T3 (en) 2017-03-01
US20110123564A1 (en) 2011-05-26
WO2011014794A1 (en) 2011-02-03
US8865182B2 (en) 2014-10-21
MX2012001404A (en) 2012-06-01
US20150086579A1 (en) 2015-03-26
EP2459716B1 (en) 2016-08-17
RU2012107702A (en) 2013-09-10
EP2459716A1 (en) 2012-06-06

Similar Documents

Publication Publication Date Title
IN2012DN01827A (en)
EA201390866A1 (en) PHILOVIRUS VACCINES BASED ON SEROTIP 26 Adenoviruses AND SEROTIP 35
CY1119284T1 (en) PARTICULAR SUBJECTS WITH VIRUS-PROTEIN SOLUTIONS (VLPs)
MX2014006361A (en) Recombinant gallid herpesvirus 3 (mdv serotype 2) vectors expressing antigens of avian pathogens and uses thereof.
PH12013502322A1 (en) Hendra and nipah virus g glycoprotein immunogenic compositions
MX2019006722A (en) Chimpanzee adenovirus constructs with lyssavirus antigens.
MX347997B (en) Newcastle disease virus vectored avian vaccines.
IL215430A (en) Immunogenic compositions and vaccines for immunization against viruses and use thereof
NZ602278A (en) Bluetongue virus recombinant vaccines and uses thereof
MX344103B (en) Newcastle disease virus vectored herpesvirus vaccines.
MX2013010620A (en) Non-pathogenic serotype 4 fowl adenovirus (fadv-4) and viral vector thereof.
WO2011130627A3 (en) Chimpanzee adenoviral vector-based filovirus vaccines
MX2016014187A (en) ADENOVIRUS THAT INCLUDES A FRACTION OF ALBUMIN UNION.
AR090706A1 (en) METHOD FOR PREPARING TENSIOACTIVE PEPTIDES
NZ608143A (en) Recombinant modified vaccinia virus ankara (mva) influenza vaccine
WO2012065105A3 (en) Chimeric flavivirus vaccines
WO2011057254A3 (en) Simian adenoviral vector-based vaccines
PH12017501100A1 (en) Recombinant swinepox virus and vaccines
ZA201007880B (en) Expression vector encoding alphavirus replicase and the use thereof as immunological adjuvant
CO6670515A2 (en) Parapoxvirus Vectors
PH12013500122A1 (en) Parapoxvirus vectors
WO2011163446A3 (en) Pan-lyssavirus vaccines against rabies
EP2504029A4 (en) Compositions, methods and uses for expression of enterobacterium-associated peptides
CO6300795A2 (en) AN ADENOVIRIC VECTOR OF SIMIO FOR USE IN A VACCINE
MX2013013812A (en) Genetic vaccines against hendra virus and nipah virus.